Many biomarkers, including tumour mutation burden (TMB), PD-L1 expression, microsatellite instability (MSI) and Epstein–Barr virus (EBV) infection status, have been proposed to identify susceptibility to PD-1/PD-L1 inhibitors5,6. This evidence concerns the gene PDCD1 and neoplasm.